PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
45.67
+0.17 (+0.37%)
At close: 4:02PM EDT

45.67 0.00 (0.00%)
After hours: 4:21PM EDT

Stock chart is not supported by your current browser
Previous Close45.50
Open45.54
Bid45.66 x 800
Ask45.68 x 800
Day's Range45.23 - 46.22
52 Week Range36.28 - 80.66
Volume1,031,951
Avg. Volume1,246,382
Market Cap6.211B
Beta (3Y Monthly)1.88
PE Ratio (TTM)54.69
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.84 (1.85%)
Ex-Dividend Date2019-05-30
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire29 days ago

    Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo

    Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the United States.

  • PR Newswirelast month

    INVESTOR ALERT: Monteverde & Associates PC Launches Legal Inquiry Regarding the Acquisition

    NEW YORK , May 22, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
    PR Newswirelast month

    Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%

    TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.

  • Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
    PR Newswire2 months ago

    Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day

    Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.

  • PR Newswire2 months ago

    Global Oral Care Leader Ranir® Agrees to be Acquired by Leading Global Self-Care Company Perrigo

    Combines Two Consumer-Focused Self-Care Companies Dedicated to Meeting Customer Needs; Expands Ability to Deliver Millions of Affordable Healthy Smiles Worldwide GRAND RAPIDS, Mich. , May 9, 2019 /PRNewswire/ ...

  • Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products
    PR Newswire2 months ago

    Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products

    DUBLIN, May 9, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750 million on a cash-free, debt-free basis, or approximately $685 million net of cash tax benefits on a present value basis. Ranir is the largest private label oral care company globally, with a comprehensive portfolio of 300+ highly customized oral care solutions including power toothbrush heads, power toothbrush handles, whitening strips, manual toothbrushes, floss, dentures and travel kits that it sells into over 50 countries worldwide.

  • Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation
    PR Newswire2 months ago

    Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation

    DUBLIN , May 8, 2019 /PRNewswire/ --  GAAP ("reported") net sales were $1.2 billion , reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. ...

  • Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation
    PR Newswire2 months ago

    Perrigo To Divest Animal Health Business For $185 Million In Cash As Part Of Consumer Self-Care Transformation

    TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (PETQ) in a transaction valued at $185 million in cash. Perrigo CEO and President Murray S. Kessler commented, "We are pleased to have reached an agreement with PetIQ on selling our Animal Health business and look forward to working with them to ensure a seamless transition. In calendar year 2018, Perrigo realized $94 million in net sales and $0.08 of adjusted diluted EPS from the Animal Health business.

  • GlobeNewswire2 months ago

    PetIQ, Inc. Reports Record First Quarter 2019 Financial Results

    First Quarter 2019 Net Sales Increased 29% Year-Over-Year to $148.4 MillionReiterates Full Year 2019 Outlook Enters Into Definitive Agreement to Acquire Perrigo Animal Health.

  • Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation
    PR Newswire2 months ago

    Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation

    TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss the results and 2019 guidance at its Investor Day on May 9, 2019. The company also announced that Perrigo President and Chief Executive Officer, Murray S. Kessler, will present at the 2019 Goldman Sachs Global Staples Forum at 2:00 PM EDT on Tuesday, May 14, 2019. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com).

  • Perrigo Increases Its Dividend By 11%
    PR Newswire2 months ago

    Perrigo Increases Its Dividend By 11%

    TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company, approved an 11% increase to the company's quarterly dividend to $0.21 per share from $0.19 per share. This dividend increase marks the 16th consecutive year Perrigo has increased its dividend. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).

  • Perrigo To Host Investor Day
    PR Newswire2 months ago

    Perrigo To Host Investor Day

    The event will feature presentations from Murray S. Kessler, President and Chief Executive Officer, as well as members of the Company's leadership team. Perrigo Company is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%
    PR Newswire3 months ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%

    TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Sernivo® (betamethasone dipropionate) Spray 0.05%. Perrigo previously settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate) Spray 0.05% brought by Promius Pharma LLC. Terms of the settlement remain confidential. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "Today's announcement marks our second tentative approval this year, in addition to four previously approved abbreviated new drug applications received in 2019.

  • Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%
    PR Newswire3 months ago

    Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold.  The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.  Visit Perrigo online at (http://www.perrigo.com). Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • GlobeNewswire3 months ago

    Sol-Gel Technologies Reports Full Year 2018 Financial Results and Provides Corporate Update

    Company met all milestones in 2018 and this year expects to report Phase III top-line results for Epsolay® and TWIN, potentially best-in-class papulopustular rosacea and acne.

  • Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer
    PR Newswire3 months ago

    Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer

    TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the global finance, tax, internal audit, investor relations, corporate communications, business development and treasury functions. Mr. Silcock joins Perrigo having been CFO of both public and private equity held companies for over 20 years.

  • Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%
    PR Newswire3 months ago

    Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%

    DUBLIN , March 18, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™" today announced it has received tentative approval ...

  • GlobeNewswire4 months ago

    Recent Analysis Shows Veeva, Mobile TeleSystems OJSC, Jacobs Engineering Group, Perrigo Company plc, AstraZeneca, and Primoris Services Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Perrigo Confirms Patent Challenge for Generic Version of Nascobal®
    PR Newswire4 months ago

    Perrigo Confirms Patent Challenge for Generic Version of Nascobal®

    TASE) today announced that Endo Pharmaceuticals Inc. initiated patent litigation on March 1, 2019 in the United States District Court for the District of Delaware regarding Perrigo's Paragraph IV Abbreviated New Drug Application for cyanocobalamin nasal spray 500mcg, asserting patents listed in the Orange Book for Nascobal®. Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This ANDA filling and subsequent patent challenge further demonstrates our commitment to enhance our pipeline and product offering in the extended topical space. Perrigo Company is dedicated to making lives better by bringing high "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at (http://www.perrigo.com).

  • ACCESSWIRE4 months ago

    Final Deadline - Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 4, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors with losses exceeding $25K that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" ...

  • GlobeNewswire4 months ago

    DEADLINE TODAY: UPDATE for YRCW, PRGO and YRIV: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, March 04, 2019 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..

  • ACCESSWIRE4 months ago

    Final Deadline Alert - Perrigo Company plc (PRGO) Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 3, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors with losses exceeding $25K that a class action lawsuit has been filed against Perrigo Company plc ("Perrigo" ...

  • ACCESSWIRE4 months ago

    DEADLINE ALERT - YRCW, PRGO & CNTF - - Bronstein, Gewirtz & Grossman, LLC

    NEW YORK, NY / ACCESSWIRE / March 3, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed againstthe following publicly-traded companies. You can review ...

  • Business Wire4 months ago

    PERRIGO INVESTOR ALERT: Rosen Law Firm Reminds Perrigo Company plc Investors of Important March 4, 2019 Deadline in Securities Class Action Lawsuit – PRGO

    Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Perrigo Company plc from November 8, 2018 through December 20, 2018, inclusive of the important March 4, 2019 deadline in the securities class action lawsuit filed against the company.

  • GlobeNewswire4 months ago

    SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Perrigo Company plc - March 4 Deadline – PRGO

    Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Perrigo Company plc (PRGO) from November 8, 2018 through December 20, 2018, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Perrigo investors under the federal securities laws. To join the Perrigo class action, go to http://pawarlawgroup.com/cases/perrigo-company-plc/ or call Vik Pawar, Esq.